Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 3/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28894439 | 0.84 | ADORA1 (0.30) | ADORA1 | |
| SCHEMBL14239072 | 0.80 | STS (0.36) | STSGPR119RORCESR2 | |
| SCHEMBL1484967 | 0.77 | STS (0.34) | STSGPR119RORCESR2 | |
| SCHEMBL212403 | 0.76 | PDK4 (0.46) | STSGPR119PDK4ADORA1ESR2 | |
| SCHEMBL25489364 | 0.76 | KLK7 (0.32) | STSGPR119RORC | |
| SCHEMBL28806075 | 0.76 | MAPK1 (0.33) | STSGPR119RORC | |
| SCHEMBL28842057 | 0.76 | MAPK1 (0.33) | STSGPR119RORC | |
| SCHEMBL1303497 | 0.76 | DRD2 (0.34) | — | |
| SCHEMBL29023204 | 0.75 | STS (0.32) | STSGPR119RORCADORA1 | |
| SCHEMBL3434214 | 0.75 | STS (0.39) | STSGPR119PDK4ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4598916-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| CN-115697994-B | Fused quinazoline derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-11739098-B2 | Substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3710440-B1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230098244-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | BIAL R&D INVEST S A (PT) | 2022-12-22 | — | — | US | disclosed |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3710440-A1 | SUBSTITUTED INDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111448190-A | Substituted indole compounds | 百时美施贵宝公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | LIANG PENG (CN) | 2013-04-25 | — | — | US | disclosed |
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, G6PC1, PIK3C2B | STS 1712/4885GPR119 835/4885BUB1 2762/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | STS 4080/4885GPR119 2581/4885BUB1 1843/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | STS 1842/4885GPR119 1280/4885BUB1 2665/4885 |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, PIK3CD, AKT2 | STS 872/4885GPR119 393/4885BUB1 977/4885 |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | STS 4109/4885GPR119 1084/4885BUB1 2459/4885 |
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | ASAH2, ASAH1, GBA1 | STS 637/4885GPR119 1919/4885BUB1 4757/4885 |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, NCOR1, NCOR2 | STS 4663/4885GPR119 428/4885BUB1 3745/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | STS 1978/4885GPR119 1588/4885BUB1 2587/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | STS 2970/4885GPR119 610/4885BUB1 4180/4885 |
| US-20230098244-A1 | SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, HTR7 | STS 2488/4885GPR119 92/4885BUB1 4408/4885 |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, HTR7 | STS 2488/4885GPR119 92/4885BUB1 4408/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | STS 1842/4885GPR119 1280/4885BUB1 2665/4885 |
| US-11739098-B2 | Substituted indole compounds | TLR7, TLR1, HTR7 | STS 2488/4885GPR119 92/4885BUB1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.